Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BI 655064

Drug Profile

BI 655064

Alternative Names: BI-655064

Latest Information Update: 09 Aug 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Class Antirheumatics; Monoclonal antibodies; Urologics
  • Mechanism of Action CD40 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Lupus nephritis
  • No development reported Idiopathic thrombocytopenic purpura; Rheumatoid arthritis

Most Recent Events

  • 27 Jul 2021 Boehringer Ingelheim completes a phase II trial for Lupus nephritis (Adjunctive treatment) in Greece, Australia, Canada, Czech Republic, France, Germany, Hong Kong, Italy, Japan, Malaysia, Mexico, Philippines, Poland, Portugal, South Korea, Spain, Thailand, United Kingdom and the US (SC) (EudraCT2017-003101-17) (NCT03385564)
  • 02 Jun 2021 Efficacy and adverse events data from a phase II trial in Lupus nephritis presented at the 22nd Annual Congress of the European League Against Rheumatism (EULAR-2021)
  • 18 Aug 2020 Boehringer Ingelheim completes a phase-II clinical trial in Lupus nephritis (Adjunctive treatment) in USA, Australia, Austria, Canada, Czech Republic, France, Germany, Greece, Hong Kong, Italy, Japan, South Korea, Malaysia, Mexico, Philippines, Portugal, Spain, Turkey, Thailand, Poland, Serbia and the UK (SC) (NCT02770170)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top